Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.53 |
| ▸ | EPOR | P19235 | 4/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.49 |
| ▸ | CHRNG | P07510 | 2/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.49 |
| ▸ | CHRND | Q07001 | 2/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830379 | 1.00 | ALOX5 (0.53) | ALOX5EPORCHRNA1CHRNGCHRNB1 | |
| SCHEMBL6827714 | 1.00 | ALOX5 (0.53) | ALOX5EPORCHRNA1CHRNGCHRNB1 | |
| SCHEMBL6831056 | 0.87 | EPOR (0.56) | ALOX5EPORLTB4RLTB4R2REN | |
| SCHEMBL6828005 | 0.86 | CHRND (0.49) | CHRNA1CHRNGCHRNB1CHRNDREN | |
| SCHEMBL7707896 | 0.86 | CHRND (0.49) | CHRNA1CHRNGCHRNB1CHRNDREN | |
| SCHEMBL6831117 | 0.86 | CHRND (0.49) | CHRNA1CHRNGCHRNB1CHRNDREN | |
| SCHEMBL6827545 | 0.86 | CHRND (0.49) | CHRNA1CHRNGCHRNB1CHRNDREN | |
| SCHEMBL6740997 | 0.84 | ALOX5 (0.62) | ALOX5LTB4RLTB4R2LTA4H | |
| SCHEMBL6830073 | 0.73 | EPOR (0.40) | EPORCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL6741455 | 0.72 | MMP2 (0.47) | ALOX5LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | claimed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | claimed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | claimed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | claimed |
| EP-1125925-A1 | Amine derivatives for the treatment of apoptosis | Applied Research Systems ARS Holding N.V. (AN) | 2001-08-22 | — | — | EP | claimed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | disclosed |
| EP-1125925-A1 | Amine derivatives for the treatment of apoptosis | Applied Research Systems ARS Holding N.V. (AN) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | ALOX5 536/4885EPOR 1207/4885CHRNA1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.